4-cyano-2-fluorophenylhydrazine hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-cyano-2-fluorophenylhydrazine hydrochloride
• 英文别名: 3-Fluoro-4-hydrazinylbenzonitrile hydrochloride；3-fluoro-4-hydrazinylbenzonitrile;hydrochloride
• 化学式: C₇H₆FN₃*ClH
• mdl: MFCD11848461
• 分子量: 187.604
• InChiKey: GIGHSTAVPPPHDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.36
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-cyano-2-fluorophenylhydrazine hydrochloride 、 4-(4-氟苯基)-2,4-二氧代丁酸甲酯 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以55%的产率得到methyl 1-(4-cyano-2-fluorophenyl)-5-(4-fluorophenyl)-1Hpyrazole-3-carboxylate
  参考文献：
  名称：

  Development of 1,5-Diaryl-Pyrazole-3-Formate Analogs as Antifungal Pesticides and Their Application in Controlling Peanut Stem Rot Disease

  摘要：

  3-氯吡啶基团赋予化合物6与甲基异硫氰酸甲酯和噻嗪酰胺对硬皮病菌的抗真菌作用相当，且呈剂量依赖性。

  DOI：

  10.3389/fmicb.2021.728173
• 作为产物：
  描述：

  3-氟-4-氨基苯腈 在 potassium nitrite 、 lithium metabisulfite 、 盐酸 作用下， 以 水 为溶剂， 以94.7%的产率得到4-cyano-2-fluorophenylhydrazine hydrochloride
  参考文献：
  名称：

  Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts

  摘要：

  本发明提供了一种连续流程，用于合成苯肼盐和取代苯肼盐。重氮化、还原、酸性水解和酸化与酸类创新地集成在一起。使用苯胺或取代苯胺的酸性液体、重氮化试剂、还原剂和酸类作为原料，通过合成过程获得苯肼衍生物盐，这是一个包括重氮化、还原、酸性水解和酸化的三步连续串联反应。所述的合成过程是一种集成解决方案，是在一个集成反应器中进行的。集成反应器的进料口连续填充原料。在集成反应器中，重氮化、还原、酸性水解和酸化被连续有序地进行，苯肼盐或取代苯肼盐在集成反应器的出口处获得，没有中断。总反应时间不超过20分钟。

  公开号：

  US20190152896A1

文献信息

• Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts
  申请人：SHANGHAI HYBRID—CHEM TECHNOLOGIES

  公开号：US11040938B2

  公开（公告）日：2021-06-22

  The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

  本发明提供了一种合成苯肼盐和取代苯肼盐的连续流工艺。重氮化、还原、酸性水解和酸盐化被创新性地整合在一起。以苯胺或取代苯胺的酸性液体、重氮化试剂、还原剂和酸为原料，通过重氮化、还原、酸性水解和盐化三步连续串联反应的合成工艺，获得苯肼衍生物盐。所述合成工艺是一种一体化解决方案，在一体化反应器中进行。集成反应器的进料口连续注入原料。在一体化反应器中，重氮化、还原、酸性水解和盐化连续有序地进行，在一体化反应器的出口处不间断地得到苯肼盐或取代苯肼盐。总反应时间不超过 20 分钟。
• Discovery of (3<i>S</i>,3a<i>R</i>)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2<i>H</i>-benzo[<i>g</i>]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy
  作者：Marvin J. Meyers、Graciela B. Arhancet、Susan L. Hockerman、Xiangyang Chen、Scott A. Long、Matthew W. Mahoney、Joseph R. Rico、Danny J. Garland、James. R. Blinn、Joe T. Collins、Shengtian Yang、Horng-Chih Huang、Kevin F. McGee、Jay M. Wendling、Jessica D. Dietz、Maria A. Payne、Bruce L. Homer、Marcia I. Heron、David B. Reitz、Xiao Hu

  DOI：10.1021/jm100505n

  日期：2010.8.26

  We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (M R) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.
• US4059434A
  申请人：——

  公开号：US4059434A

  公开（公告）日：1977-11-22
• US4111681A
  申请人：——

  公开号：US4111681A

  公开（公告）日：1978-09-05
• US4108628A
  申请人：——

  公开号：US4108628A

  公开（公告）日：1978-08-22